<DOC>
	<DOCNO>NCT02604836</DOCNO>
	<brief_summary>This study investigate participant satisfaction ( include compliance , preference , tolerability ) once-monthly Bonviva woman post-menopausal osteoporosis osteopenia transition once-weekly alendronate risedronate . The anticipated time study treatment 6 month , target sample size 1776 individual .</brief_summary>
	<brief_title>A Study Ibandronate ( Boniva ) Evaluate Satisfaction Women With Post-Menopausal Osteoporosis Osteopenia</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Women receive onceweekly alendronate risedronate treatment prevention postmenopausal osteoporosis great equal ( &gt; = ) 3 month Inability stand sit upright &gt; =60 minute Hypersensitivity bisphosphonates Inability swallow tablet whole Malignant disease diagnose within previous 10 year ( except resect basal cell cancer ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>